Literature DB >> 31479153

Minimally invasive parathyroid carcinoma-A missing entity between parathyroid adenoma and carcinoma: Scintigraphic and histological features.

Priyanka Singh1, Shelvin Kumar Vadi2, Uma Nahar Saikia3, Ashwani Sood2, Divya Dahiya4, Ashutosh Kumar Arya1, Arunanshu Behera4, Soham Mukherjee1, Sapara Mohin Arvindkumar1, Sanjay Kumar Bhadada1.   

Abstract

PURPOSE: Minimally invasive parathyroid carcinoma (MIPC) is clinically and biochemically comparable with parathyroid adenoma (PA) though histopathologically differ from PA. MIPC is an intermediate of PA and parathyroid carcinoma (PC). In literature, there is no definite criterion to diagnose MIPC. Our aim was to evaluate and characterize the imaging and biochemical parameters with histological characteristics of MIPC.
METHODOLOGY: Ten patients with MIPC were recruited from (single centre) Indian PHPT registry (www.indianphptregistry.com) from January 2014 to July 2018. Clinical, biochemical, imaging and histological features of MIPC patients were reviewed.
RESULTS: The mean age of MIPC patients (n = 10; 3 males) was 39.9 ± 11.3 years (range: 17-50). All patients had an elevated preoperative parathyroid hormone (iPTH) level ranging from 427 to 2138 pg/mL (median: 1328). MIBI scan showed intensely avid and enlarged parathyroid tumours in all patients; LIPT in 6, RIPT in 3 and ectopic mediastinal in 1 with mean size of the tumours was 2.8 ± 1.1 cm. The mean of maximum standardized uptake value (SUVmax) of MIPC in F-18 fluorocholine PET/CT was 6.7 ± 1.1 (range 6.0-8.3). The mean tumour weight was 12 ± 9.5 g (range: 1.09-28). All MIPC patients had identified capsular invasion in 80% and vascular invasion in 50% only but there was no local invasion, lymph nodal or distant metastasis. The mean Ki-67 labelling index was 3.2 ± 2.7 (range 1.1-10).
CONCLUSION: The study concluded that MIPC patients are less aggressive (on the basis of imaging and histopathological findings) and should be differentiated from parathyroid adenoma and carcinoma.
© 2019 John Wiley & Sons Ltd.

Entities:  

Keywords:  minimally invasive parathyroid carcinoma; parathyroid adenoma; parathyroid carcinoma; primary hyperparathyroidism

Year:  2019        PMID: 31479153     DOI: 10.1111/cen.14088

Source DB:  PubMed          Journal:  Clin Endocrinol (Oxf)        ISSN: 0300-0664            Impact factor:   3.478


  5 in total

1.  Aberrant Epigenetic Alteration of PAX1 Expression Contributes to Parathyroid Tumorigenesis.

Authors:  Priyanka Singh; Sanjay Kumar Bhadada; Ashutosh Kumar Arya; Uma Nahar Saikia; Naresh Sachdeva; Divya Dahiya; Jyotdeep Kaur; Maria Luisa Brandi; Sudhaker Dhanwada Rao
Journal:  J Clin Endocrinol Metab       Date:  2022-01-18       Impact factor: 6.134

2.  Reduced Calcium Sensing Receptor (CaSR) Expression Is Epigenetically Deregulated in Parathyroid Adenomas.

Authors:  Priyanka Singh; Sanjay Kumar Bhadada; Divya Dahiya; Ashutosh Kumar Arya; Uma Nahar Saikia; Naresh Sachdeva; Jyotdeep Kaur; Maria Luisa Brandi; Sudhaker Dhanwada Rao
Journal:  J Clin Endocrinol Metab       Date:  2020-09-01       Impact factor: 5.958

3.  The EANM practice guidelines for parathyroid imaging.

Authors:  Petra Petranović Ovčariček; Luca Giovanella; Ignasi Carrió Gasset; Elif Hindié; Martin W Huellner; Markus Luster; Arnoldo Piccardo; Theresia Weber; Jean-Noël Talbot; Frederik Anton Verburg
Journal:  Eur J Nucl Med Mol Imaging       Date:  2021-04-10       Impact factor: 9.236

4.  Case Report and Systematic Review: Sarcomatoid Parathyroid Carcinoma-A Rare, Highly Malignant Subtype.

Authors:  Yongchao Yu; Yue Wang; Qingcheng Wu; Xuzi Zhao; Deshun Liu; Yongfu Zhao; Yuguo Li; Guangzhi Wang; Jingchao Xu; Junzhu Chen; Ning Zhang; Xiaofeng Tian
Journal:  Front Endocrinol (Lausanne)       Date:  2021-12-15       Impact factor: 5.555

5.  GCM2 Silencing in Parathyroid Adenoma Is Associated With Promoter Hypermethylation and Gain of Methylation on Histone 3.

Authors:  Priyanka Singh; Sanjay Kumar Bhadada; Divya Dahiya; Uma Nahar Saikia; Ashutosh Kumar Arya; Naresh Sachdeva; Jyotdeep Kaur; Arunanshu Behera; Maria Luisa Brandi; Sudhaker Dhanwada Rao
Journal:  J Clin Endocrinol Metab       Date:  2021-09-27       Impact factor: 6.134

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.